Your browser doesn't support javascript.
loading
Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in mice.
Jarvis, Rebecca; Josephine Ng, Shu Fun; Nathanson, Anna J; Cardarelli, Ross A; Abiraman, Krithika; Wade, Fergus; Evans-Strong, Aidan; Fernandez-Campa, Marina P; Deeb, Tarek Z; Smalley, Joshua L; Jamier, Tanguy; Gurrell, Ian K; McWilliams, Lisa; Kawatkar, Aarti; Conway, Leslie C; Wang, Qi; Burli, Roland W; Brandon, Nicholas J; Chessell, Iain P; Goldman, Aaron J; Maguire, Jamie L; Moss, Stephen J.
Affiliation
  • Jarvis R; Discovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Josephine Ng SF; Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
  • Nathanson AJ; Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
  • Cardarelli RA; Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
  • Abiraman K; Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
  • Wade F; Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
  • Evans-Strong A; Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
  • Fernandez-Campa MP; Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
  • Deeb TZ; Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
  • Smalley JL; Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
  • Jamier T; Discovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Gurrell IK; Discovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • McWilliams L; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
  • Kawatkar A; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Boston, MA, USA.
  • Conway LC; Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
  • Wang Q; Discovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.
  • Burli RW; Discovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Brandon NJ; Discovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.
  • Chessell IP; Discovery, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Goldman AJ; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Maguire JL; Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.
  • Moss SJ; Department of Neuroscience, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA; Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1 6BT, UK. Electronic address: stephen.moss@tufts.edu.
Cell Rep Med ; 4(3): 100957, 2023 03 21.
Article in En | MEDLINE | ID: mdl-36889319
ABSTRACT
Hyperpolarizing GABAAR currents, the unitary events that underlie synaptic inhibition, are dependent upon efficient Cl- extrusion, a process that is facilitated by the neuronal specific K+/Cl- co-transporter KCC2. Its activity is also a determinant of the anticonvulsant efficacy of the canonical GABAAR-positive allosteric benzodiazepines (BDZs). Compromised KCC2 activity is implicated in the pathophysiology of status epilepticus (SE), a medical emergency that rapidly becomes refractory to BDZ (BDZ-RSE). Here, we have identified small molecules that directly bind to and activate KCC2, which leads to reduced neuronal Cl- accumulation and excitability. KCC2 activation does not induce any overt effects on behavior but prevents the development of and terminates ongoing BDZ-RSE. In addition, KCC2 activation reduces neuronal cell death following BDZ-RSE. Collectively, these findings demonstrate that KCC2 activation is a promising strategy to terminate BDZ-resistant seizures and limit the associated neuronal injury.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Status Epilepticus / Symporters Type of study: Prognostic_studies Limits: Animals Language: En Journal: Cell Rep Med Year: 2023 Document type: Article Affiliation country: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Status Epilepticus / Symporters Type of study: Prognostic_studies Limits: Animals Language: En Journal: Cell Rep Med Year: 2023 Document type: Article Affiliation country: Reino Unido